RAUTENSIN Drug Patent Profile
✉ Email this page to a colleague
When do Rautensin patents expire, and when can generic versions of Rautensin launch?
Rautensin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in RAUTENSIN is alseroxylon. Additional details are available on the alseroxylon profile page.
Summary for RAUTENSIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 18 |
Patent Applications: | 4,317 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RAUTENSIN at DailyMed |
US Patents and Regulatory Information for RAUTENSIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | RAUTENSIN | alseroxylon | TABLET;ORAL | 009215-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |